


Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Amendments are illustrated by showing deletions ~~by strikethrough~~ or by double brackets for deletions of five or fewer characters and additions by underlining)

Claims 1-17 (canceled)

Claim 18 (currently amended): A compound of the
formula:



wherein

A¹ is a D- or L-isomer of an aromatic amino acid or is
deleted;

A³ is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa or an aliphatic amino
acid;

A⁸ is a D- or L-isomer selected from the group consisting of
Thr, Ser, an aromatic amino acid or an aliphatic amino acid;

each of R₁ and R₂, is, independently, H or substituted or
unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle,
heterocycle lower alkyl, E₁SO₂ or E₁CO wherein E₁ is aryl, aryl
lower alkyl, heterocycle or heterocycle lower alky and said
substituent is halo, lower alkyl, hydroxy, halo lower alkyl or
hydroxy lower alkyl; and

R₃, together with the carbonyl group of A⁸ attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

provided that a disulfide bond links the sidechains of A² and A⁷; and

further provided that if A¹ is D-Phe or p-NO₂-Phe, A³ is Phe or Tyr and A⁶ is Thr or Val, then A⁸ is β-Nal.

19 (currently amended): A compound of claim 18, wherein A¹ is the D- or L-isomer of β-Nal, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NΘO₂, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NΘO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, F₅-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A³ is β-Nal, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, F₅-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val; and A⁸ is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NΘO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NΘO₂, Igl, Tyr(Bzl), or β-Nal.

20 (currently amended): A compound of claim 19, wherein A¹ is the D- or L-isomer of β-Nal, Phe, p-F-Phe, Trp, p-

Cl-Phe, or p-CN-Phe; A³ is Tyr, Tyr[[]](I), or Pal; A⁶ is Val, Tle, Nle, Ile, or Leu; A⁸ is p-F-Phe, β -Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R₁ is H, CH₃CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R₂ is H, and R₃, together with the carboxy group of A⁸ attached thereto, are reduced to form H or CH₃OH.

21 (original): A compound of claim 20, wherein A³ is Pal.

22 (currently amended): A compound of claim 19, of the formula:

H₂- β -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂- β -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO)- β -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂- β -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-[[]]3-hydroxymethyl)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂- β -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO)- β -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R,3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-[[]]3-hydroxy)propylamide;

H₂-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H(CH₃CO) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

H₂-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

H₂-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (CH₃CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

H₂-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (CH₃CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

H₂-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
(H) (CH₃CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-[[]](2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
H₂-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
(H) (CH₃CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-[[]](2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
H₂-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
(H) (CH₃CO) Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

H₂-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (CH₃CO) Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl) ethylamide;

H₂-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl) ethylamide;


H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl) ethylamide;

H₂-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide; or

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

or a pharmaceutically acceptable salt thereof.

23 (previously presented): A compound of the formula:



wherein

A¹ is a D- or L-isomer of an aromatic amino acid, or is deleted;

A² is a D-aromatic amino acid or a D-aliphatic amino acid,

A³ is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;

A⁷ is an aromatic amino acid or an aliphatic amino acid;

A⁸ is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R₁ and R₂, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E₁SO₂ or E₁CO wherein E₁ is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

R₃ is OH, NH₂, C₁₋₁₂ alkoxy, or NH-Y-CH₂-Z, wherein Y is a C₁₋₁₂ hydrocarbon moiety and Z is H, OH, CO₂H, or CONH₂, or R₃, together

with the carbonyl group of A⁸ attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

provided if A² is D-Cys or D-Pen and A⁷ is Cys or Pen, then a disulfide bond links the sidechains of A² and A⁷, and

further provided that if A¹ is D-Phe or p-NO₂-Phe, A² is D-Cys, A³ is Phe or Tyr, A⁶ is Thr or Val and A⁷ is Cys, then A⁸ is β-Nal.

24 (previously presented): A compound of claim 23, wherein A¹ is an L- amino acid and A² is a D-aromatic amino acid.

25 (currently amended): A compound of claim 24, wherein each of A¹[[,]]₁ A³, and A⁷, is, independently, β-Nal, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or N $\overline{\text{O}}$ O₂, F₅-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A² is D-β-Nal, D-o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-F₅-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val; and A⁸ is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or N $\overline{\text{O}}$ O₂, o-X-Phe wherein X is H,

Applicant : Coy *et al.*
Serial No. : 10/712,081
Filed : November 13, 2003
Page : 12

OH, CH₃, halo, OCH₃, NH₂, CN, or N Θ O₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or N Θ O₂, Igl, Tyr (Bzl), or β -Nal.

26 (previously presented): A compound of claim 25, wherein A¹ is β -Nal or Phe, A² is D-Cpa or D-Phe; A³ is Phe or Tyr; A⁶ is Abu, Thr, or Val; A⁷ is Phe; and A⁸ is Thr; R₁ is H, CH₃CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R₂ is H; and R₃ is NH₂.

27 (currently amended): A compound of claim 25 of the formula:

H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
H₂-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H₂-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H₂- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (CH₃CO)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-[[]]D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H₂- β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (CH₃CO)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH₂;

H_2 - β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (CH₃CO)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-[[]]D-Cpa
-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-
Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
 H_2 - β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (CH₃CO)- β -Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-D-Cpa-Pal-
D-Trp-Lys-Thr-Phe-Thr-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)- β -Nal-D-
Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH₂;
 H_2 - β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;
(H) (CH₃CO)- β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)- β -Nal-[[]]D-Cpa
-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-[[]] β -
Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂;
 H_2 - β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe- β -Nal-NH₂; or
 H_2 - β -Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂; or
a pharmaceutically acceptable salt thereof.

28 (original): A compound of claim 23, wherein A¹ is a
D-amino acid and A² is a D-aromatic amino acid.

29 (currently amended): A compound of claim 28, wherein each of A¹ and A², is, independently, D-β-Nal, D-o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, D-F₅-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; each of A³ and A⁷, ~~is~~, independently, is β-Nal, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, F₅-Phe, Trp, Dip, 2-Pal, His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, β-Ala, Gaba, or Val; and A⁸ is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, o-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, m-X-Phe wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂, Igl, Tyr(Bzl), or β-Nal.

30 (currently amended): A compound of claim 29, wherein A¹ is D-β-Nal or D-Phe; A² is D-Cpa or D-Phe; A³ is Phe or Tyr; A⁶ is Thr or Val; A⁷ is Phe; A⁸ is Thr; R₁ is H, CH₃CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-[[]]1-piperizineethanesulfonyl; R₂ is H; and R₃ is NH₂.

31 (previously presented): A compound of claim 29 of the formula:

H₂-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH₂;

H₂-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H₂-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H₂-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H₂-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH₂; or

a pharmaceutically acceptable salt thereof.

32 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

33 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

34 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

35 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound

according to claim 18 or a pharmaceutically acceptable salt thereof.

36 (currently amended): A method of imaging cells having somatostatin receptors which comprises administering to ~~said~~ a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 18 having Tyr(I).

37 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

38 (previously presented): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

39 (previously presented): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

40 (previously presented): A method of enhancing wound healing in a subject in need thereof, which comprises

administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

41 (previously presented): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

42 (currently amended): A method of imaging cells having somatostatin receptors which comprises administering to ~~said a~~ a subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 23 having Tyr(I).

43 (previously presented): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.